Monath, M.D., Elizabeth Fowler, Ph.D., Casey T. Johnson, D.O., John Balser, Ph.D., Merribeth J. Morin, Ph.D., Maggie Sisti, B.S., and Dennis W. Trent, Ph.D.: An Inactivated Cell-Culture Vaccine against Yellow Fever Yellow fever, a lethal, mosquito-borne flavivirus disease, occurs in tropical South Africa and America. A live attenuated vaccine developed in 1936 is widely used, with 20 million doses distributed annually approximately. Although remarkably immunogenic, the 17D vaccine may cause serious viscerotropic and neurotropic adverse anaphylaxis and events. Viscerotropic disease is usually a fulminant 17D virus illness of the liver and visceral organs resembling normally acquired yellow fever.His career as an urological oncologist started as a founding person in the Genito-Urinary Cancer group of the European Organisation for Study and Treatment of Cancers . He offered the EORTC in a number of features including President from 1988 till 1991. He served twelve months as managing release director of the European Journal of Cancer tumor. He served as treasurer of the Union Internationale contre le Cancer , after an extended term service in various positions including secretary general from 1998 to 2006. His recent interest is focused on the organisation and support of cancer tumor patients associations generally and prostate malignancy associations in particular.